Efficacy and Tolerance of Single-dose Azithromycin for Treatment of Chlamydial Cervicitis During Pregnancy by Miller, Joseph M.
Infectious Diseases in Obstetrics and Gynecology 3:189-192 (1995)
(C) 1996 Wiley-Liss, Inc.
Efficacy and Tolerance of Single-Dose Azithromycin for
Treatment of Chlamydial Cervicitis During Pregnancy
Joseph M. Miller, Jr.
Department of Obstetrics and Gynecology, Louisiana State University Medical Center,
New Orleans, LA
ABSTRACT
Objective: The intent of this study was to determine the efficacy and tolerance of single-dose oral
azithromycin in the treatment ofpregnant women with endocervical chlamydial carriage.
Methods: A retrospective review of clinic records over a two-year period identified pregnant
patients treated with a single 1-g dose of azithromycin for chlamydial carriage. The side effects and
subsequent chlamydial carriage (test of cure) were noted.
Results: A total of 146 pregnant women treated with azithromycin was reviewed. A cure rate of
96% was found. Side effects were reported in 5%.
Conclusions:A single 1-g oral dose of azithromycin is effective for the treatment ofchlamydia and
is well tolerated in pregnant women. (C) 1996 Wiley-Liss, Inc.
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hlamydia trachomatis carriage in pregnancy
poses concerns for the patient, her unborn
child, and her sexual partner. Erythromycin is now
recommended, but it is associated with significant
gastrointestinal side eff’ects. 2’3 Noncompliance is
common, occurring in nearly 40% of patients.
4 A
new drug, azithromycin, in a single 1-g dose, has
been approved for the treatment of chlamydial cer-
vicitis in nonpregnant individuals. A small pro-
spective study in pregnant women showed that
azithromycin was associated with cure rates similar
to those of erythromycin but was significantly bet-
ter tolerated.
5 We elected to use azithromycin pref-
erentially because of potential enhanced compli-
ance, reduced side effects, and excellent cure rate.
The only alternate drug freely available was eryth-
romycin. Presented is our experience with azithro-
mycin’s efficacy and tolerance in over 100 pregnant
patients followed in our practice.
SUBJECTS AND METHODS
The patient population attended a community-based
prenatal and family planning clinic adjacent to 2
low-income housing projects between January 1,
1993, and December 31, 1994. Surveillance data
previously identified ch!amydial cervicitis as being
present in greater that 20% of the patients attending
this clinic.
6 The patients included in this report
were identified by an audit of all clinic records.
Only the patients with follow-up information about
side effects were included. Five patients lacking
such information were excluded. Patient character-
istics are given in Table 1.
Cervical swabs were analyzed by direct DNA
assay (Gen-Probe, San Diego, CA), routinely per-
formed on all obstetric patients at their initial visits
and again at 34 weeks of gestation. This test has a
sensitivity of 76-96% and a specificity of 98%.7’
The pregnant women with positive chlamydial
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TABLE I. Population characteristics
No. of
Characteristic patients
Ethnic background
Afro-American 142
Caucasian 2
Hispanic 2
Parity
0 101
28
2 9
>3 8
Maternal age in years
<15 10
16-17 37
18-19 49
20-24 34
25-30 12
>30 4
screens were offered treatment with g of azithro-
mycin on site and were observed for 30 min after
the oral medication was administered. The patients
were questioned later as to the occurrence of side
effects, including nausea, vomiting, diarrhea, and
abdominal pain. This information was obtained by
patient recall at a subsequent clinic visit; diaries
were not kept. The patients were instructed to ab-
stain from intercourse until their sexual partners
had completed treatment. Their partners were re-
ferred to a sexually transmitted disease (STD) clinic
available to all patients. The occurrence of chlamy-
dia as an STD was reported to the State Health
Department. A test of cure was generally obtained
10-14 days after treatment. The patient’s age, race,
parity, and pregnancy outcome (gestational age and
birth weight) were obtained from a chart review.
The presence of a positive test for other STDs
(Venereal Disease Research Laboratory reaction
[VDRL], human immune deficiency virus anti-
body [HIV] confirmed by western blot, gonorrhea
by Gen-probe, hepatitis B surface antigen, and hu-
man papillomavirus by pap smear) at any time
during pregnancy was also recorded. These tests
were obtained at the initial visit. The VDRL and
both chlamydia and gonorrhea assays by Gen-probe
were repeated at 34 weeks of gestation. Patients
with signs or symptoms of genital herpes were cul-
tured; otherwise, cultures were not routinely ob-
tained.
RESULTS
The treated patients were primarily young. Ten
patients were < 15 years, 37 were 16-17 years, 49
were 18-19, 34 were 20-24, 12 were 28-30, and
4 were >30 years. There were 101 nulliparas; 28
had previously delivered child, 9 had delivered 2
children, and 8 had delivered 3 or more children.
One hundred forty-two patients were Afro-Ameri-
can, 2 were Hispanic, and 2 were Caucasian. Two
patients had twins. The initial positive screens for
chlamydia were reported and the patients were
treated: 35/146 in the first trimester, 71 in the
second trimester, and 40 in the third trimester.
Other STDs were identified. A carriage of
Neisseria gonorrhoeae was found in 33 patients. Four
had positive herpes cultures during pregnancy. Two
patients had positive VDRLs. One patient was pos-
itive for hepatitis B surface antigen. Another pa-
tient was HIV positive. Four patients had evidence
of human papillomavirus on their pap smears.
Twenty-two of the treated patients were chlamydia
negative at the time of their initial obstetric evalua-
tions, but subsequently were positive.
Azithromycin was generally well tolerated, with
only 8/146 patients experiencing side effects. Seven
patients experienced nausea. Six of them vomited
within 2 h of treatment; the seventh complained of
abdominal pain as well. One patient developed
diarrhea. Cefixime, 400 mg, was also administered
subsequent to azithromycin to 22 patients with pos-
itive tests for gonorrhea 30-60 min after the initial
treatment for chlamydia. Other antibiotics, were
initiated several hours later, including metronida-
zole in 9 patients (4 for bacterial vaginosis and 5
for trichomonas); clindamycin vaginal cream for 2
patients with bacterial vaginosis; and, for urinary-
tract infections, ampicillin for 3 patients and ni-
trofurodantoin for patient. Of the 6 patients who
vomited, received metronidazole and another ce-
fixim within 2 h, but before vomiting. Two of the
6 patients who vomited were empirically retreated
with azithromycin; all 6 had negative tests of cure.
The treatment was successful in 132/138 pa-
tients who had tests of cure. Eight patients either
delivered (n 1) or were lost to follow-up (n 7).
Reinfection, defined by a subsequent positive test
after the test of cure was negative, was found in
15/67 patients who were retested during the same
pregnancy after the negative test of cure. Retreat-
ment with azithromycin was routinely done for
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reinfection and was effective in all 10 for whom
tests of cure were subsequently obtained. The re-
treatment was not included in the treatment efficacy
or side effect data.
The 6 patients who failed therapy had tests of
cure obtained 19, 3 5, 5 0, 51, 61, and 67 days after
treatment. Reinfection rather than treatment fail-
ure may well have been present.
Late miscarriage (at 15, 16, and 18 weeks of
gestation) occurred in 3 patients. A review of the
records indicated that 2 delivered 4 days after treat-
ment, for an incompetent cervix. A third patient
delivered 15 days after treatment. A fourth patient
with spotting prior to treatment aborted 4 days later
while in the first trimester. One patient underwent
a pregnancy termination. Delivery before 3 7 weeks
of gestation occurred in 19/12 5 patients. The deliv-
ery information was unavailable in 16. The birth
weight was 1,500-2,499 g for 15 infants and
<1,500 g in 1. The pregnancy outcomes were
reflective of the patient population served.
6
DISCUSSION
A single 1-g dose of azithromycin was found to be
an effective treatment of C. trachomatis endocervi-
cal carriage in pregnant women, supporting a
smaller study in pregnant women and a larger one
in nonpregnant women.
9 The side effects, which
did not vary substantially from those previously
reported, were less common than those reported
with erythromycin use in pregnancy.
2 Single-dose
treatment, which is both effective and well toler-
ated, holds great promise for patients who may
already be experiencing nausea while pregnant or
for patients who maybe noncompliant with antibi-
otics. Noncompliance occurs more often among
younger patients and those experiencing side ef-
fects.
4 Currently, amoxicillin is held to be a reason-
able alternative treatment for chlamydial endocer-
vical carriage, with a cure rate of 85-98%. l’ll
We believe the cure rate with azithromycin of96%,
together with the low rate of side effects, ease of
administration, and absence of discontinuance by
the patient, is sufficient to select it over the alternate
drugs of amoxicillin and erythromycin for the pop-
ulation served by our program. There is little risk
to the fetus from treatment with this class B drug
(Pfizer Labs prescribing information, February,
1992). Class B drugs have no evidence of risk in
humans: either animal findings show risk but hu-
man findings do not or, in the absence of adequate
human studies, animal findings are negative.
12
However, sufficient follow-up with azithromycin,
which is yet to be published, would provide a high
level of reassurance.
Reinfection was a frequent occurrence in our
study. Appropriate follow-up studies for chlamydia
appear warranted in our population. Twenty-two
percent of the treated and "cured" patients who
were retested demonstrated chlamydia carriage later
in the same pregnancy. The population characteris-
tics of our study patients, being primarily young
Afro-Americans residing in an urban setting, are
recognized risk factors for recurrent infections in
women.
13 Instructions to the patient may need to
reemphasize the importance of condoms in the pre-
vention ofSTDs as well as appropriate evaluation,
treatment, and follow-up of sexual partners.
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